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Abstract
Background and Aims: Compounds that act on GABA-receptors produce anti-hyperalgesia in animal models, but little is
known on their effects in humans. The aim of this study was to explore the potential usefulness of GABA-agonism for the
control of pain in humans. Two agonists at the benzodiazepine-binding site of GABAA-receptors (clobazam and
clonazepam) were studied using multiple experimental pain tests. Positive results would support further investigation of
GABA agonism for the control of clinical pain.
Methods: In a randomized double-blind crossover design, 16 healthy male volunteers received clobazam 20 mg,
clonazepam 1 mg and tolterodine 1 mg (active placebo). The area of static hyperalgesia after intradermal capsaicin
injection was the primary endpoint. Secondary endpoints were: area of dynamic hyperalgesia, response to von Frey hair
stimulation, pressure pain thresholds, conditioned pain modulation, cutaneous and intramuscular electrical pain thresholds
(1, 5 and 20 repeated stimulation), and pain during cuff algometry.
Results: For the primary endpoint, an increase in the area of static hyperalgesia was observed after administration of
placebo (p,0.001), but not after clobazam and clonazepam. Results suggestive for an anti-hyperalgesic effect of the
benzodiazepines were obtained with all three intramuscular pain models and with cuff algometry. No effect could be
detected with the other pain models employed.
Conclusions: Collectively, the results are suggestive for a possible anti-hyperalgesic effect of drugs acting at the GABAA-
receptors in humans, particularly in models of secondary hyperalgesia and deep pain. The findings are not conclusive, but
support further clinical research on pain modulation by GABAergic drugs. Because of the partial results, future research
should focus on compounds acting selectively on subunits of the GABA complex, which may allow the achievement of
higher receptor occupancy than unselective drugs. Our data also provide information on the most suitable experimental
models for future investigation of GABAergic compounds.
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Introduction
Chronic pain is still a largely unresolved problem. Effective
pharmacological approaches need to target alterations in the
nociceptive system that are responsible for pain and disability.
Extensive animal research has demonstrated that pain conditions
are associated with plastic changes of the central nervous system
that alter the processing of the somatosensory and nociceptive
input [1]. These changes result in reduced pain thresholds to
sensory stimuli, enhanced pain after supra-threshold stimulation
and enlargement of the areas of local and referred pain. All these
manifestations have been consistently detected in human chronic
pain [2] and are likely to be highly relevant in terms of
amplification of pain and disability. Thus, pharmacological
targeting of neuroplastic changes is one important aim of
translational pain research.
A relevant aspect of neuroplastic changes in inflammatory and
neuropathic conditions is the reduction in inhibitory glycinergic
and GABAergic control of dorsal horn neurons: a reduction in the
GABAA -mediated endogenous inhibitory control within the
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central nervous system leads to exaggerated pain and hyperalgesia
[3]. Potentiation of GABAA receptor-mediated synaptic inhibition
by benzodiazepines reverses pathologically increased pain sensi-
tivity in animal studies [4,5]. Subtype-selective compounds
targeting the alpha2 and/or alpha3 subunit of the GABAA
receptor produce antihyperalgesia in mice and rats without
sedation and without tolerance induction [6]. These findings open
new perspectives for a more selective targeting of pain pathways
with GABAergic drugs.
Benzodiazepines produce anti-hyperalgesia in animal models by
acting as agonists at the benzodiazepine-binding site of GABAA
receptor [4]. These compounds can therefore be studied to explore
the potential usefulness of GABA-agonism in human pain
conditions. To date, little is known on the effects of GABAA
receptor targeting drugs on nociceptive processes in humans. A
review on the efficacy of non-opioid analgesics in human
experimental pain models did not include these drugs [7]. We
are not aware of comprehensive experimental human studies on
the efficacy of drugs acting at GABA-receptors. This information
is important to evaluate the potential clinical usefulness of these
compounds in pain management and to guide future research.
The aim of the present study was to analyze the effect of two
agonists at the benzodiazepine-binding site of GABAA receptors
(shortly named as benzodiazepines) on different mechanisms of
pain processing, using a multimodal experimental testing proce-
dure in healthy volunteers. Clonazepam was studied because it is
probably the most commonly prescribed benzodiazepine in
chronic pain management. Clobazam is another benzodiazepine
that may cause less sedation than clonazepam [8,9] and might also
have anti-hyperalgesic properties. Clobazam has been therefore
selected as test compound, with clonazepam as positive control
and tolterodine as active placebo.
The ultimate aim of the study was to explore the potential
usefulness of GABA-agonism for the control of clinical pain,
providing guide for future clinical research. The results were
positive for a subgroup of experimental pain modalities, support-
ing further investigation of GABA-agonism in clinical pain.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethic statement
The study was approved by the cantonal ethics committee
(No. 152/09), registered in the Clinical Trials Protocol Registra-
tion System (NCT01011036), and performed in accordance with
the Declaration of Helsinki. Written informed consent was
obtained from all participants.
Design
This is a randomized double-blind crossover study, using pain
assessment methods that explore different nociceptive mecha-
nisms. Clobazam 20 mg, clonazepam 1 mg and tolterodine 1 mg
(active placebo) were compared. At the end of each session the
benzodiazepine antagonist flumazenil 0.2 mg was administered to
evaluate whether the observed effects can be reversed.
Setting
The experiments were performed at the University Department
of Anesthesiology and Pain Therapy, Inselspital Bern, Switzerland.
Pharmacokinetic and pharmacogenomic investigations were per-
formed at the Division of Clinical Pharmacology and Toxicology,
University Hospital of Geneva.
Subjects
Volunteers were recruited by advertisement at the Inselspital
and at the University of Bern by the first author (P.V.). Sixteen
healthy volunteers were tested between December 2009 and July
2010 (figure 1). They received 200 Swiss Francs for each session
and a total of 800 Swiss Francs if they completed all the three
experiments.
Inclusion criteria were: european ethnicity (in order to minimize
pharmacogenetic variations), male gender (in order to avoid
possible variation due to hormonal changes during the menstrual
cycle), age 18–55 years old, induction of static mechanical
hyperalgesia by capsaicin as described below and status as non
smoker or moderate smoker (#10 cigarettes/day).
Exclusion criteria were: current or past history of drug or
alcohol abuse, intake of any psychotropic drug currently or in the
last month, chronic alcohol intake, any concomitant illness,
current or regular intake of any drugs that might affect pain or
nociception.
Study medication
Clobazam, clonazepam and tolterodine were given orally to the
same volunteers in a randomized order on three different sessions,
with a minimal washout interval between two consecutive sessions
of two weeks. All subjects were tested in the morning and had been
instructed to take a very light breakfast at home. The minimum
interval between breakfast and drug intake was 3 h.
Clobazam (UrbanylH, Sanofi-Aventis AG, Meyrin, Switzerland)
is a benzodiazepine. To our knowledge, it has never been tested
for analgesic or antihyperalgesic properties. Unlike 2 mg clonaz-
epam, 20 mg clobazam did not affect significantly cognitive and
psychomotor functions, possibly because of its unusual 1–5
chemical structure [9]. Clonazepam (RivotrilH, Roche Pharma
Figure 1. Flowchart of the study.
doi:10.1371/journal.pone.0043896.g001
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AG, Reinach, Switzerland) is probably the benzodiazepine most
widely used for the treatment of clinical pain, although the
evidence behind this practice is weak [10]. It was therefore chosen
as positive control.
The doses of clobazam and clonazepam were chosen based on
the following considerations. Clonazepam is typically prescribed in
chronic neuropathic pain at doses between 0.5 and 1 mg, and
2 mg a day is an average dose for this indication [11]. Typical
anticonvulsant starting doses of clonazepam and clobazam are
0.5–2 mg and 10–20 mg, respectively [12]. A dose of 20 mg of
clobazam has been shown to be less sedative than 1 mg of
clonazepam and should be equipotent [8]. Therefore these doses
have been chosen for the present study.
Tolterodine (DetrusitolH, Pharmacia Gmbh, Pfizer Group,
Berlin, Germany) is an anticholinergic compound [13]. Anticho-
linergic compounds usually cause some sedation and dry mouth; to
our knowledge, they are devoid of analgesic effects. Because of its
sedative properties, tolterodine has been chosen as an active
placebo in order to keep double blinding.
Flumazenil (AnexateH, Roche Pharma AG, Reinach, Switzer-
land) selectively antagonizes or attenuates the effects of benzodi-
azepines on GABAA receptors [14]. To minimize the risk of
seizure, a dose of 0.2 mg iv was chosen.
The subjects received the study medications in a randomized
order. A computer-generated random list was prepared by the
hospital pharmacy and was known only by the hospital pharmacy.
The drugs were enclosed by the hospital pharmacy in the same
type of capsule to assure blinding. The pharmacy delivered the
blinded capsules to the investigators, numbered according to the
defined randomization order. The first author (P.V.) assigned
participants to the experimental sessions.
Tests
Endpoints. The primary endpoint was the area of static
hyperalgesia induced by intradermal capsaicin injection. The
additional measures were secondary endpoints.
General methodological aspects. Because of the very
limited information on which experimental pain models would
be sensitive to the effects of benzodiazepines, we applied a
multimodal testing procedure that is expected to explore different
aspects of nociceptive processes. The rationale is summarized in
table 1. In particular, we applied models of hyperalgesia, tissue-
specific pain sensitivity (cutaneous vs. muscular), sensitivity to short
and ongoing painful stimulation, temporal summation (increase in
pain perception during stimulation of constant intensity), stimulus-
response function (dependency of pain rating from different
stimulation intensities) and conditioned pain modulation (explor-
ing endogenous pain modulation).
Before starting each session, trainings of the pain tests were
performed until the subjects were familiar with the testing
procedures.
All the tests were applied on the dominant side, except the cold
pressor test and cuff algometry (see below for explanations). All
subjects but one were right-handed. Each subject was tested on the
same side in all three experimental sessions.
Volunteers were not allowed to see the area tested and any read-
outs from any instruments.
Intradermal capsaicin. Intradermal injection of capsaicin
causes a brief stinging/burning pain at the injection site followed
by development of secondary hyperalgesia, i.e. hyperalgesia
detected at surrounding (not injected) skin [15,16]. Secondary
hyperalgesia after intradermal capsaicin is the result of sensitiza-
tion of the central nervous system, which is one of the most
relevant aspects of neuroplastic changes [17]. This model was
sensitive to the action of GABAergic compounds in animal studies
[18].
The capsaicin solution was prepared by the Hospital Pharmacy
and underwent sterile filtration into sterile septum-sealed vials.
The sterile solution (1 mg/ml) was placed into sterile syringes and
used for intradermal injection at room temperature. The skin
temperature was measured using a digital thermometer, and was
32uC+/21 in all subjects.
Subjects remained semi-supine during the experiment. Before
capsaicin injection, the skin of the forearm was cleaned using an
antiseptic wipe and allowed to air dry. The injection site was
marked midway between the elbow and the wrist. Using a surgical
skin marker, 4 lines were drawn through the injection site, so that
they intersected the corners of a regular octagon (figure 2). These
lines were marked every 0.5 cm from the center to the edges using
a predefined grid. This resulted in the creation of triangles
radiating from the intersection of the 4 lines outwards. We
determined the area of hyperalgesia by adding the areas of each
triangle in which hyperalgesia was recorded.
Using a 1-ml tuberculin syringe fitted with a 27-gauge
disposable needle, 100 ml capsaicin were injected epidermally into
the skin, at the intersection of the 4 vectors previously drawn. A
white skin elevation appeared during injection ensuring correct
injection.
Table 1. Experimental pain tests employed.
Mechanisms explored Rationale Methods
Secondary hyperalgesia
(primary endpoint)
The drugs could reduce the area of hyperalgesia around the site of
primary nociception, which is the result of sensitization of central
neural structures
Area of hyperalgesia after intradermal capsaicin injection
Tissue-specific pain sensitivity The drugs could act differently for nociceptive stimulation arising
from different tissues (skin vs. muscle)
Response to cutaneous vs. muscular electrical
stimulation
Temporal summation The drugs could attenuate central summation processes induced
by repeated nociceptive stimulation (temporal summation)
Repeated electrical stimulation (5 stimuli) of the skin and
muscle
Sensitivity to ongoing painful
stimulation
The drugs could be effective for tonic continuous painful
stimulation
Cuff algometry and cold pressor test
Stimulus-response function The effect of drugs could depend on the stimulation intensity Pain rating after von Frey stimulation at different
intensities
Endogenous modulation The drugs could enhance endogenous inhibitory mechanisms
of central pain processes
Conditioned pain modulation (CPM) by ice water test
and pressure algometry
doi:10.1371/journal.pone.0043896.t001
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Static mechanical hyperalgesia was judged to be present when
the subjects reported that applying a 512 mN von Frey Hair, 5
and 30 minutes after capsaicin injection, elicited pain with an
intensity of at least 4 using a numerical rating scale (NRS, whereby
0= no pain and 10=worst pain). Only these subjects were
included in the study. In order to document pain induction, the
subject recorded pain intensity at injection and 5 minutes post-
injection using a 10 cm visual analogue pain scale (VAS), whereby
0= no pain and 10=worst pain imaginable.
The area of secondary hyperalgesia was assessed using a
calibrated 512 mN von Frey hair. The punctuated probe was
moved along the 8 radial lines defined above, starting approxi-
mately 6 cm away from the site of injection, at each mark in steps
of 0.5 cm. The weighted von Frey hair was placed gently on the
skin and the load was applied for 2 seconds. The volunteers were
asked to report when the pricking sensation changed to a pain
sensation. At least 4 seconds elapsed between consecutive stimuli.
This procedure was repeated for each vector. The number
corresponding to the marker at which sensation changes as
described above was noted and the individual numbers were used
to calculate the area of hyperalgesia.
The area of dynamic mechanical hyperalgesia was determined
by gently stroking a hand-held cotton wool tip on a 1 cm strip of
the skin, at a rate of approximately 1 cm/s. Subjects were asked to
report when the sensation changed from a non-painful to a painful
sensation. The borders of dynamic hyperalgesia were delineated
similarly to the determination of static hyperalgesia.
Additionally, mechanical pain sensitivity was assessed using a set
of seven weighted pinprick stimuli to obtain a stimulus-response
function. The test was applied 1 cm inside the outer border of the
pinprick hyperalgesic area, using a set of 7 graded von Frey hair
mechanical stimulators with fixed stimulus intensities (custom-
made at Aalborg University, Denmark). The flat contact area of
the stimulators has a 0.2 mm diameter, and the 7 stimulators exert
forces of 8, 16, 32, 64, 128, 256 and 512 mN. The order of
stimulation was defined randomly by computer. The stimulators
were applied at a rate of 2 s on/2 s off. Subjects were asked to give
a pain rating for each stimulus on a 10 cm VAS. Two assessments
for each stimulation were made and the mean of these 2
measurements was used for the data analysis.
Pressure stimulation. Pain detection and tolerance thresh-
olds were measured with an electronic pressure algometer
(Somedic, Ho¨rby, Sweden) applied at the center of the pulp of
the 2nd toe. The probe had a surface area of 1 cm2. The pressure
was increased from 0 at a rate of 30 kPa/s to a maximum pressure
of 1200 kPa. Pain detection threshold was defined as the point at
which the pressure sensation turned to pain. Pain tolerance
threshold was defined as the point at which the subject felt the pain
as intolerable. If the threshold was not reached at 1200 kPa, this
value was considered as threshold. Three assessments were made
and the mean of these 3 measurements were used for the data
analysis.
Conditioned pain modulation (CPM). This method ex-
plores the endogenous modulation of nociceptive input. Under
normal conditions, pain after application of a ‘‘test’’ nociceptive
stimulus is attenuated by the application of an additional
conditioning noxious stimulus to a remote body region, reflecting
diffuse endogenous inhibition [19,20]. In the present study,
pressure pain detection threshold and cold pressure test (see
below) were used as test and conditioning stimuli, respectively. An
increase in pressure pain detection threshold immediately after
cold pressure test was an indication of CPM.
Cold pressor test. The subjects placed their hand into a
container filled with ice water. In order to maximize heterotopic
stimulation, the hand contralateral to the side of pressure
stimulation was used. The water was regularly mixed to maintain
the temperature near to 0uC. The temperature of the water near
the hand was monitored by a thermometer with a digital display
(60.1uC). The subjects were asked to keep the hand in the water
until they felt an intolerable sensation of pain and were forced to
remove the hand from the container, with a maximum time of
2 min.
Pressure stimulation after cold pressor test. Pressure
pain detection threshold was measured again at the same time as
the subject was withdrawing the hand from the water (one single
measurement). CPM was measured as the difference in pressure
pain detection threshold between measurements after and before
the cold pressure test.
Cutaneous single electrical stimulation. Electrical stimu-
lation was performed through electrodes placed distal to the lateral
malleolus. A 25 ms, train-of-five, 1 ms, square-wave impulse
(perceived as one stimulus), was delivered by a computer-
controlled constant current stimulator (Digitimer DS7A, Neuro-
spec, Letchworth Garden City, UK). The current intensity was
increased from 1 mA in steps of 0.5 mA until a pain sensation was
evoked.
Three assessments were made and the mean of these 3
measurements was used for the data analysis.
Cutaneous repeated (5 stimuli) electrical
stimulation. The stimulus burst used for single stimulus was
repeated 5 times at 2 Hz, at constant intensity. The current
Figure 2. Capsaicin model. The dots represent the points where
stimulation was applied. The circle in the center of the hectagon is the
site of capsaicin injection.
doi:10.1371/journal.pone.0043896.g002
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intensity of the 5 stimuli was increased from 1 mA in steps of
0.5 mA until the subjects felt pain during the last 2–3 of the 5
stimuli (indicating temporal summation) [21].
Three assessments were made and the mean of these 3
measurements was used for the data analysis.
Cutaneous repeated (20 stimuli) electrical
stimulation. The stimulus burst used for single stimulus was
repeated for a train of 20 pulses at 2 Hz, at an intensity
corresponding to the temporal summation threshold. During this
10 s stimulation, pain intensity was continuously rated by the
subject with an electronic VAS, and the area under the curve
(AUC) was computed. Additionally, the maximal VAS during
stimulation was recorded.
Intramuscular electrical stimulation (1, 5 and 20
stimuli). A needle was placed in the tibialis anterior muscle,
14 cm distal from the caudal end of the patella and 20 mm in
depth. The same single and repeated stimulation patterns and the
same procedure described for cutaneous stimulation were used.
Cuff algometry. A tourniquet cuff was applied to the middle
of the leg, at the level of the heads of the gastrocnemius and soleus
muscle [22]. The cuff was applied at the side contralateral to the
side of electrical stimulation in order not to interfere with the
positioning of the intramuscular electrodes. During stimulation,
the volunteer rated the pain intensity on an electronic VAS scale.
The cuff was inflated with compressed air until VAS 6 was reached
[22]. The maximum allowed inflating pressure was 200 kPa. The
pressure was maintained for 10 min or until the subjects rated the
pain as intolerable. The area under the curve VAS-time was
computed. For those subjects who felt intolerable pain before
10 min, the time when the cuff was deflated was recorded and
VAS 10 was extrapolated until 10 min. Additionally, the maximal
VAS during inflation was recorded.
Psychomotor performance. The psychomotor performance
was assessed by the digit symbol substitution test (DSST), a
subscale of the Wechsler Adult Intelligence Scale. The DSST
evaluates the ability to concentrate and modifications in processing
information [23]. It is a two-minute paper-and-pencil test. The
subject was asked to replace digits with corresponding symbols
according to a code given on the same sheet of paper. The score
consists in the total number and the correct number of symbols
drawn.
Timing of the experiment. The flow of the experiment is
illustrated in figure 3. After training, basal values for the pain tests
were determined. The study medication was given immediately
after the intradermal injection of capsaicin. Thus, basal values
were recorded for all tests, except for those related to capsaicin
injection. Because of the relatively short duration of hyperalgesia
induced by capsaicin, the recordings of basal values before drug
administration would yield a too short testing procedure [17].
The following tests were performed starting 30, 60, 90 and
120 min after medication: all assessments related to capsaicin
injection and all cutaneous electrical pain measurements. Pressure
pain, conditioned pain modulation (CPM), intramuscular electri-
cal pain tests, cuff algometry and DSST were performed 120 min
after drug intake.
Flumazenil was injected 2:45 h after intake of the study
medication. After 15 min, the whole battery of tests was
performed.
The occurrence of any side effect was recorded every 30 min,
starting at drug administration.
Four hours after intake of the study medication, the volunteers
were discharged after control of blood pressure, heart rate and
clinical evaluation of cognitive functions.
Pharmacokinetic and pharmacogenetic investigations
Pharmacokinetic and pharmacogenetic investigations were
undertaken on clobazam as the test compound. For pharmaco-
kinetics, blood samples (6 ml) were collected in heparinized tubes
at 0.5, 1, 1.5, 2, 4 and 24 hours after drug administration. A
specific LC-MS/MS assay was developed and validated in the
laboratory of the Division of Clinical Pharmacology and
Toxicology of the Geneva University Hospital.
The pharmacogenetic investigation was made in order to
control for this factor in case of outlier concentrations of clobazam.
It took place 1–4 weeks before the first testing session to evaluate
the metabolic activity of cytocrhome P-450 involved in clobazam
metabolization.
Figure 3. Time plan of the experiment. Horizontal arrow: Testing time; ZZ: Resting time; EX: Medical examination, installation of the testing
equipment and training measures; CT: Measures on the area of capsaicin hyperalgesia; ET: Cutaneous electrical stimulation; ED: Intramuscular
electrical stimulation, pressure stimulation, cold pressor test, conditioned pain modulation and cuff algometry; BT: Psychomotor performance test; b:
Blood sample.
doi:10.1371/journal.pone.0043896.g003
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Phenotype: in vivo activities of 2C19 and 3A4/5 was assessed
using micro-doses of omeprazole 2 mg (2C19) and midazolam
0.1 mg (CYP3A4/5), both administered orally at the same time.
Two hours after the drugs intake, 2 venous blood samples (6 ml)
were collected into heparinized tubes and centrifuged. According
to a standardized protocol, the phenotype was determined by
calculating the metabolic ratio between deconjugated midazolam
and its metabolite 19-OH-midazolam for CYP3A4 and the ratio of
omeprazole and its metabolite OH-omeprazole for CYP2C19 2 h
after the drug intake.
Genotype: DNA extracted from blood samples was used for
genotype determination. Three single nucleotide polymorphisms
(SNP) of the CYP2C19 gene were determined, CYP2C19*2
(c.681G.A), CYP2C19*3 (c.636G.A) and CYP2C19*17 (g.-
806C.T) using polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) as described previously.
Deviations from study protocol
No important changes to methods or outcomes after the trial
commenced were done. The following minor deviations from the
study protocol were made.
The body side to which the pain tests were applied was not
selected by randomization, as originally planned; we decided to
perform most tests on the dominant side in order to place the
volunteer with the tested side close to the devices; see section 2.6,
‘‘general methodological aspects’’.
The skin temperature before application of capsaicin was
measured, but not recorded; since the skin temperature in the
range of 32uC+/21 was a condition for performing the
experiment and no analysis on this parameter was planed, we
did not record the individual temperatures; see section 2.6,
‘‘intradermal capsaicin’’.
For the cold pressor test, we renounced to record the pain
intensity continuously using an electronic VAS, because this
measurement was not an outcome and in order to simplify the
experiment.
The recordings of the DSST test were limited to 120 min and
after flumazenil, in order to simplify the experiment.
Sample size calculation
The primary variable was the area of static hyperalgesia
induced by capsaicin injection. The additional measures were
secondary variables. No data on the drugs under investigations
were available. In a previous study that employed the capsaicin
model, pregabalin caused a reduction in the area of hyperalgesia
of 10.91 cm2, with a standard deviation of 11.54 [24]. This results
in a sample size of 11, adopting a 5% level for statistical
significance and an 80% power, two-sided. In a conservative
prediction of the effects of the drug that we investigated, we
planned to study 16 subjects.
Statistical analysis
The main analysis was a two-way repeated measures ANOVA
(SigmaStat 3.5, Systat Software Inc, Chicago, Il, USA), with
medication and time as factors of repetition. Non normally
distributed data were rank transformed before performing the
ANOVA. The analysis tested primarily for the interaction of drug
with time (timepoint of the measurements). In case of no
significant interaction, we tested the overall effects of the ‘‘factors’’
drug and time. In models with significant interactions, the main
effects of the factors drug and time are not interpretable and are
therefore not presented. Pairwise comparisons were performed by
the Holm-Sidak method.
Because of the high variability of the plasma levels of clobazam
(see results), a pharmacokinetic-pharmacodynamic modeling was
not feasible. Since the time at which clobazam reached the peak
plasma concentration was very variable across subjects, we
assumed that its effect might be better detected by considering
only the highest drug effect before administration of flumazenil
(referred to as ‘‘peak value analysis’’). We therefore performed a
repeated-measure ANOVA by considering as value after medica-
tion only the highest drug effect before administration of
flumazenil (referred to as ‘‘peak value analysis’’). This was done
for all three drug sessions, in order to keep an unbiased placebo
control. For threshold measurements, the peak was the highest
value, reflecting the maximum analgesic effect; conversely, for area
of hyperalgesia and VAS assessments, the peak analgesic effect
corresponded to the lowest value of these parameters.
Finally, we also assumed that including subjects with delayed
peak plasma level of clobazam or too low plasma levels during the
phase of testing may prevent the detection of drug effects. We
therefore repeated the ANOVA analyses after exclusion of subjects
with clobazam plasma peaks beyond 2 h after study medication
and plasma concentrations lower than 200 mg/ml during the same
period (n= 8) (referred to as ‘‘subgroup analysis’’). The limit of
200 mg/ml was chosen because this is the described mean peak
concentration after an oral dose of 10 mg [25].
A p-value,0.05 was considered as statistically significant.
Because of the explorative nature of the study, the p-values were
not adjusted for multiple comparisons.
Results
The flowchart of the study is displayed in figure 1. In order to
obtain 16 complete experiments, we assessed 20 subjects for
eligibility, recruited 18 subjects and randomized 17 of them. In all
participants capsaicin elicited pain with an intensity of at least 4
(NRS scale). One of these volunteers was excluded from the
analysis because his area of hyperalgesia after capsaicin injection
was larger than the vectors drawn on the skin, rendering the
measure of the primary endpoint impossible. All the remaining 16
tested male subjects completed the study. Their mean age was 26.1
years (SD 4.2) and the BMI was 22.6 kg/m2 (SD 2.6).
The mean values and standard deviations of all performed tests
are presented in table 2. For the sake of brevity and to avoid
repetition, part of the results of the many statistical analysis are
omitted in the following text: here we present the most relevant
data, while all statistical analyses are reported in details in table 3.
In table 4, an overview of the results is presented.
Area of static hyperalgesia after capsaicin
The pain rating on the VAS-scale immediately after injection of
capsaicin was 9.6 (SD 0.7). After five minutes it decreased to 5.8
(SD 1.9). There was no statistically significant difference in the
pain rating after among the 3 experimental sessions (p = 0.926 and
0.417 immediately after injection and at 5 min, respectively).
Main analysis. For the area of static hyperalgesia, there was
a statistically significant interaction between ‘‘factors’’ drug and
time (p = 0.016). Pairwise multiple comparisons within each drug
showed that under the placebo tolterodine a significant increase in
the area of hyperalgesia over time was observed (p,0.001),
whereas there was no statistically significant increase for clonaz-
epam and clobazam (figure 4). No statistically significant difference
among the three drug sessions after flumazenil was detected. Thus,
capsaicin injection induced a progressive increase in the area of
static hyperalgesia, which was prevented by clobazam and
clonazepam.
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Table 2. Results of the pain tests performed.
Test Drug Baseline 30 min 60 min 90 min 120 min After flumazenil
Area of static hyperalgesia (cm2) Tolterodine
Clonazepam
Clobazam
n/a
36.3 (10.6)
37.9 (13.6)
39.7 (18.6)
40.6 (11.5)
45.6 (15.3)
44.3 (17.1)
43.8 (11.9)
43.4 (14.3)
43.0 (15.0)
44.7 (10.9)
41.9 (11.6)
43.6 (16.5)
47.6 (13.7)
39.4 (12.3)
43.8 (15.0)
Area of dynamic hyperalgesia
(cm2)
Tolterodine
Clonazepam
Clobazam
n/a
20.3 (11.6)
22.4 (11.2)
22.3 (13.2)
23.3 (09.0)
19.0 (07.8)
22.9 (12.4)
23.1 (11.3)
21.7 (12.6)
22.4 (13.6)
23.3 (09.1)
16.8 (10.8)
16.7 (13.0)
24.7 (14.6)
19.2 (13.1)
21.3 (14.6)
VAS after von Frey hair 8 mN Tolterodine
Clonazepam
Clobazam
n/a
1.3 (1.5)
1.4 (1.5)
1.1 (1.2)
1.2 (1.3)
1.2 (0.9)
1.9 (3.3)
1.2 (1.4)
0.8 (0.8)
1.2 (1.4)
1.0 (0.9)
1.0 (0.8)
1.3 (1.4)
1.1 (1.2)
0.6 (0.6)
1.1 (1.1)
VAS after von Frey hair 16 mN Tolterodine
Clonazepam
Clobazam
n/a
1.7 (1.8)
1.6 (1.2)
2.0 (2.1)
1.9 (1.9)
1.8 (1.9)
2.3 (3.2)
1.6 (1.9)
1.3 (1.0)
1.4 (1.6)
1.4 (1.3)
1.4 (1.2)
1.3 (1.5)
1.1 (0.9)
1.4 (1.2)
1.3 (1.1)
VAS after von Frey hair 32 mN Tolterodine
Clonazepam
Clobazam
n/a
2.5 (1.9)
1.9 (1.5)
2.0 (1.6)
2.7 (2.2)
2.0 (2.0)
2.4 (2.8)
2.2 (1.4)
1.8 (1.4)
2.1 (2.2)
1.9 (1.3)
2.1 (1.7)
1.9 (1.9)
2.1 (1.6)
1.6 (1.4)
1.9 (1.9)
VAS after von Frey hair 64 mN Tolterodine
Clonazepam
Clobazam
n/a
3.2 (2.3)
2.8 (1.8)
2.3 (2.0)
2.9 (1.8)
2.7 (2.0)
2.5 (2.0)
2.8 (2.0)
2.1 (1.6)
2.1 (1.9)
2.3 (1.5)
2.3 (1.5)
2.7 (2.7)
2.6 (1.7)
2.2 (1.7)
2.2 (1.7)
VAS after von Frey hair 128 mN Tolterodine
Clonazepam
Clobazam
n/a
3.4 (2.2)
3.2 (4.2)
2.9 (2.0)
3.5 (2.2)
3.5 (2.0)
3.4 (2.7)
3.1 (2.0)
2.8 (1.7)
3.5 (2.3)
2.9 (2.0)
2.9 (1.9)
3.0 (2.6)
2.6 (1.5)
2.6 (1.9)
2.9 (2.1)
VAS after von Frey hair 256 mN Tolterodine
Clonazepam
Clobazam
n/a
4.2 (2.1)
4.2 (2.2)
3.3(2.3)
4.2 (2.1)
4.1 (1.8)
3.7 (2.6)
4.2 (2.0)
4.4 (2.0)
3.9 (2.5)
4.1 (2.5)
3.9 (2.2)
3.8 (2.6)
4.1(1.7)
3.8 (1.7)
3.9 (2.2)\
VAS after von Frey hair 512 mN Tolterodine
Clonazepam
Clobazam
n/a
4.9 (2.0)
5.2 (2.1)
4.5 (2.5)
5.2 (2.0)
5.1 (2.0)
4.8 (2.8)
4.9 (2.1)
5.3 (2.1)
4.9 (2.6)
4.8 (2.2)
5.0 (1.9)
4.7 (2.7)
5.0 (2.2)
4.9 (1.7)
5.1 (2.5)
Pressure pain detection threshold
(kPa)
Tolterodine
Clonazepam
Clobazam
403 (118)
416 (80)
432 (123)
n/a n/a n/a
371 (88)
383 (100)
379 (130)
382 (118)
389 (112)
393 (118)
Pressure pain tolerance threshold
(kPa)
Tolterodine
Clonazepam
Clonazepam
674 (221)
685 (172)
749 (242)
n/a n/a n/a
652 (15)
636 (147)
712 (262)
685.0 (203)
390.8 (199)
734.7 (279)
Conditioned pain modulation
(kPa)
Tolterodine
Clonazepam
Clobazam
68 (100)
70 (113)
71 (98)
n/a n/a n/a
72 (114)
85 (77)
99 (99)
77 (79)
74 (86)
58 (67)
Pain threshold after single
cutaneous electrical stimulation
(mA)
Tolterodine
Clonazepam
Clobazam
9.9 (2.2)
9.7 (3.3)
10.0 (2.9)
10.3 (2.6)
9.8 (3.5)
10.3 (3.6)
10.7 (2.3)
10.3 (3.4)
10.2 (3.8)
10.9 (2.7)
10.6 (3.6)
11.2 (3.3)
11.5 (2.3)
11.0 (3.6)
12.2 (3.9)
12.1 (2.6)
11.2 (3.9)
12.0 (4.3)
Pain threshold after 5
cutaneous electrical stimuli
(mA)
Tolterodine
Clonazepam
Clobazam
8.8 (2.3)
8.2 (3.1)
8.3 (3.0)
9.0 (2.4)
8.2 (3.0)
8.7 (3.4)
9.2 (2.2)
8.5 (2.9)
8.7 (3.4)
9.5 (2.2)
8.8 (3.2)
9.3 (2.9)
9.7 (2.1)
9.1 (3.1)
9.9 (3.3)
10.0 (2.3)
9.2 (3.3)
9.7 (3.3)
Maximal VAS during 20
cutaneous electrical stimuli
Tolterodine
Clonazepam
Clobazam
4.7 (1.5)
4.9 (1.6)
4.7 (1.8)
5.1 (1.6)
5.4 (2.0)
4.9 (2.2)
4.8 (1.8)
5.0 (2.3)
4.7 (1.9)
4.9 (1.8)
4.7 (2.1)
4.3 (2.0)
4.6 (1.8)
4.4 (1.6)
4.2 (1.8)
4.7 (1.6)
4.2 (1.6)
4.5 (1.7)
AUC of VAS during 20
cutaneous electrical stimuli
Tolterodine
Clonazepam
Clobazam
379 (155)
359 (144)
332 (142)
382 (134)
352 (131)
338 (152)
362 (155)
349 (185)
341 (167)
336 (143)
351 (141)
328 (169)
328 (144)
344 (148)
314 (146)
326 (136)
322 (137)
339 (150)
Pain threshold after single
intramuscular electrical
stimulation (mA)
Tolterodine
Clonazepam
Clobazam
1.8 (1.2)
1.8 (1.2)
1.7 (1.2)
n/a n/a n/a
2.2 (1.2)
3.0 (2.5)
3.1 (4.6)
2.7 (1.7)
4.1 (3.7)
2.5 (2.1)
Pain threshold after 5
intramuscular electrical
stimuli (mA)
Tolterodine
Clonazepam
Clobazam
1.6 (1.2)
1.6 (1.1)
1.4 (1.1)
n/a n/a n/a
1.9 (1.2)
2.3 (1.6)
2.1 (2.2)
2.2 (1.5)
2.9 (2.3)
2.2 (2.0)
Maximal VAS during 20
intramuscular electrical
stimuli
Tolterodine
Clonazepam
Clobazam
4.5 (1.6)
4.3 (1.4)
4.2 (1.5)
n/a n/a n/a
3.8 (2.4)
3.2 (2.4)
4.5 (2.5)
4.1 (2.5)
2.8 (2.0)
4.0 (1.9)
AUC of VAS during 20
intramuscular electrical
stimuli
Tolterodine
Clonazepam
Clobazam
323 (127)
307 (138)
284 (149)
n/a n/a n/a
286 (198)
236 (204)
309 (188)
316 (206)
209 (178)
292 (169)
AUC of VAS during
cuff algometry
Tolterodine
Clonazepam
Clobazam
3348 (743)
3420 (689)
3446 (539)
n/a n/a n/a
2686 (1155)
3175 (644)
3001 (831)
2918 (1021)
3225 (671)
2932 (566)
The data are expressed as mean (SD). Statistical significance is shown in table 3.
n/a: not applicable. AUC: area under the curve. VAS: visual analog scale for pain (range 0–10).
doi:10.1371/journal.pone.0043896.t002
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Table 3. Results of the ANOVA analyses on all the tests.
Test Analysis Factor Time x Drug Factor Drug Factor Time
Area of static hyperalgesia Main
Peak
Subgroup
0.016*
n/a
0.017*
n/p
0.781
n/p
n/p
n/a
n/p
Area of dynamic hyperalgesia Main
Peak
Subgroup
0.291
n/a
0.131
0.410
0.495
0.137
0.236
n/a
0.600
VAS after von Frey hair 8 mN Main
Peak
Subgroup
0.686
n/a
0.482
0.470
0.386
0.478
0.170
n/a
0.953
VAS after von Frey hair 16 mN Main
Peak
Subgroup
0.925
n/a
0.796
0.845
0.551
0.250
0.003*
n/a
0.053
VAS after von Frey hair 32 mN Main
Peak
Subgroup
0.788
n/a
0.578
0.672
0.735
0.360
0.169
n/a
0.210
VAS after von Frey hair 64 mN Main
Peak
Subgroup
0.299
n/a
0.490
0.326
0.079
0.832
0.094
n/a
0.388
VAS after von Frey hair 128 mN Main
Peak
Subgroup
0.594
n/a
0.329
0.937
0.798
0.329
0.009*
n/a
0.270
VAS after von Frey hair 128 mN Main
Peak
Subgroup
0.405
n/a
0.438
0.418
0.712
0.326
0.699
n/a
0.720
VAS after von Frey hair 512 mN Main
Peak
Subgroup
0.511
n/a
,0.001*
0.772
0.558
n/p
0.329
n/a
n/p
Pressure pain detection threshold Main
Peak
Subgroup
0.927
0.606
0.891
0.764
0.755
0.609
0.039*
0.036*
0.134
Pressure pain tolerance threshold Main
Peak
Subgroup
0.881
0.750
0.566
0.184
0.154
0.194
0.251
0.090
0.500
Conditioned pain modulation Main
Peak
Subgroup
0.855
0.855
0.725
0.850
0.850
0.717
0.346
0.346
0.521
Pain threshold after single
cutaneous electrical stimulation
Main
Peak
Subgroup
0.252
0.323
0.087
0.810
0.744
0.941
,0.001*
,0.001*
,0.001*
Pain threshold after 5 cutaneous
electrical stimuli
Main
Peak
Subgroup
0.770
0.169
0.087
0.682
0.740
0.819
,0.001*
,0.001*
,0.001*
Maximal VAS during 20
cutaneous electrical stimuli
Main
Peak
Subgroup
0.353
0.128
0.593
0.583
0.814
0.890
,0.001*
,0.002*
,0.001*
AUC of VAS during 20
cutaneous electrical stimuli
Main
Peak
Subgroup
0.340
0.708
0.072
0.628
0.702
0.482
0.145
0.063
,0.001*
Pain threshold after single
intramuscular electrical stimulation
Main
Peak
Subgroup
0.160
0.474
0.109
0.566
0.500
0.066
0.010*
,0.001*
0.051
Pain threshold after 5
intramuscular electrical stimuli
Main
Peak
Subgroup
0.153
0.386
0.042*
0.779
0.889
n/p
,0.001*
0.002*
n/p
Maximal VAS during 20
intramuscular electrical stimuli
Main
Peak
Subgroup
0.105
0.132
0.104
0.245
0.086
0.047*
0.031*
0.026*
0.113
AUC of VAS during 20
intramuscular electrical stimuli
Main
Peak
Subgroup
0.154
0.222
0.589
0.447
0.798
0.065
0.211
0.030*
0.311
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Peak value and subgroup analyses. The peak value
analysis did not yield statistically significant results. In the
subgroup analysis, there was again a significant interaction
between time and drug (p = 0.017). Pairwise multiple comparisons
within each drug showed that clonazepam significantly decreases
the area of hyperalgesia between the time-point 60 min and the
measurement after flumazenil (p = 0.004), indicating that fluma-
zenil could not abolish the clonazepam effect.
Area of dynamic hyperalgesia after capsaicin
No statistical significance was observed.
Pain intensity after von Frey hair stimulation
In the main analysis, the ‘‘factor’’ drug and interaction between
time and drug were not statistically significant for any assessment.
The peak value analysis did not yield statistically significant results.
In the subgroup analysis, the ‘‘factor’’ interaction of drug with time
was significant only for the measurement with 512 mN (p= 0.001).
The pairwise multiple comparison within each drug showed an
increase of pain rating from the measure at 30 minutes (VAS 3.2,
SD 2.8) to the assessment at 120 minutes (VAS 5.1, SD 2.9) with
clobazam (p,0.001). This isolated finding is difficult to explain
and could be the result of chance.
Table 3. Cont.
Test Analysis Factor Time x Drug Factor Drug Factor Time
AUC of VAS during cuff algometry Main
Peak
Subgroup
0.347
0.235
0.161
0.087
0.088
0.106
0.003*
0.002*
0.019*
DSST-Score Main
Peak
Subgroup
0.095
n/a
0.040*
0.133
n/a
n/p
,0.001*
n/a
n/p
The table shows the results for the main, the peak value and the subgroup analysis. The main analysis was performed on all subjects for all data. The peak value analysis
included only the basal values and the maximal effect before administration of flumazenil. The subgroup analysis included the subjects with peak plasma levels of
clobazam before administration of flumazenil and plasma concentrations of at least 200 mg/ml during the same period (n = 8). The table shows the p values for the
interaction of drug with time and for the factors drug and time. For analyses with a significant interaction, the results of the effects of the factors drug and time are not
interpretable and are therefore not presented (marked as n/p).
*: P-Values ,0.05. VAS: pain intensity as assessed by the visual analog scale (0 = no pain, 10 = worst pain imaginable). AUC: area under the curve. DSST: digit symbol
substitution test (measure of psychomotor performance). n/a: not applicable. n/p: not presented.
doi:10.1371/journal.pone.0059791.t003
Table 4. Overview of the results.
Test Main analysis Peak value or subgroup analysis
Synthesis of the
effects of the
GABA-agonists
Area of static hyperalgesia Significant increase in the area of
hyperalgesia only for tolterodine
Decrease in the area of hyperalgesia
after Clonazepam
Possible anti-
hyperalgesic effect
Area of dynamic hyperalgesia Not significant No relevant additional information No effect
Pain intensity after von Frey stimulation Not significant No relevant additional information No effect
Pressure stimulation Not significant No relevant additional information No effect
Conditioned pain modulation Not significant No relevant additional information No effect
Cutaneous single electrical stimulation Not significant No relevant additional information No effect
Cutaneous repeated (5 stimuli) electrical
stimulation
Not significant No relevant additional information No effect
Cutaneous repeated (20 stimuli) electrical
stimulation
Not significant No relevant additional information No effect
Intramuscular single electrical stimulation Significant increase in pain thresholds
only for clonazepam
Significant increase in pain thresholds only
for clonazepam in the peak value analysis
Possible analgesic
effect
Intramuscular repeated (5 stimuli) electrical
stimulation
Significant increase in pain thresholds for
clobazam and clonazepam, but not for
Tolterodine
Consistent for an increase in pain thresholds
after clobazam and clonazepam
Possible analgesic
effect
Intramuscular repeated (20 stimuli) electrical
stimulation
Not significant Significantly lower maximal VAS with
clonazepam, compared with tolterodine
and clobazam in the subgroup analysis
Possible analgesic
effect
Cuff algometry Not significant Time factor significant, favouring clobazam
and clonazepam compared to tolterodine
Possible analgesic
effect
The table synthetizes the findings of the the main, peak value and subgroup analysis. The statistical significance for ‘‘factors’’ drug and interaction of drug with time is
presented. Significance for ‘‘factor’’ time alone is omitted.
doi:10.1371/journal.pone.0059791.t004
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Pressure stimulation
For both pain detection and tolerance threshold, the ‘‘factor’’
drug and the interaction between drug and time were not
statistically significant for any analysis.
Conditioned pain modulation (CPM)
No statistical significance was observed.
Cutaneous single and repeated electrical stimulation (1, 5
and 20 stimuli)
The ‘‘factor’’ drug and the interaction between drug and time
were not statistically significant for any analysis.
Intramuscular single electrical stimulation
Main analysis. The ‘‘factors’’ drug and interaction between
drug and time were not statistically significant, whereas there was
a significant overall time effect (p = 0.01). Pairwise comparisons
within each drug revealed a significant increase in the pain
threshold only within clonazepam from baseline (1.84, SD1.23) to
the time-point after flumazenil (4.05, SD 3.74) (p,0.001).
Peak value and subgroup analyses. In the peak value
analysis, the ‘‘factors’’ drug and interaction between drug and time
were not statistically significant, whereas there was a significant
overall time effect (p = 0.015). Pairwise comparisons within each
drug revealed clonazepam to significantly increase pain detection
thresholds from baseline (9.7, SD 3.3) to peak value (11.0, SD 3.6)
(p = 0.032).
The subgroup analysis did not yield statistically significant
results.
Intramuscular repeated (5 stimuli) electrical stimulation
Main analysis. The ‘‘factors’’ drug and interaction between
drug and time were not statistically significant, whereas there was
a significant overall time effect (p,0.001). The pairwise multiple
comparison revealed a significant increase in pain thresholds for
clonazepam (p= 0.021) and clobazam (p= 0.021) between baseline
measures and 120 minutes, whereas no statistically significant
change in pain threshold after tolterodine was observed (figure 5).
Peak value and subgroup analyses. The peak value
analysis confirmed the results of the main analysis. Pairwise
comparisons within each drug revealed a significant increase in
pain detection threshold from baseline to peak value after
clonazepam (p= 0.017) and clobazam (p= 0.007), but not after
tolterodine.
In the subgroup analysis, the interaction of drug with time
(p = 0.042) was statistically significant. The pairwise multiple
comparisons showed that clonazepam significantly increased the
pain threshold from baseline (1.69 mA, SD 1.23) to 120 minutes
(2.93 mA, SD 2.00) (p,0.001), confirming the above results. The
difference persisted also after flumazenil administration (3.58 mA,
SD 2.77) (p = 0.004).
Figure 4. Static pinprick hyperalgesia after capsaicin. The area of static hyperalgesia significantly increased with the active placebo tolterodine
(p,0.001), but not with clobazam and clonazepam.
doi:10.1371/journal.pone.0043896.g004
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Intramuscular repeated (20 stimuli) electrical stimulation
In the main and peak value analysis, no statistical significance
for the ‘‘factor’’ drug and the interaction between drug and time
was observed.
In the subgroup analysis the ‘‘factor’’ drug was statistically
significant for the maximal VAS (p = 0.047). In the pairwise
comparisons among drugs, clonazepam displayed lower values
than tolterodine (p = 0.031) and clobazam (p= 0.031).
Cuff algometry
In the main and peak value analysis, the ‘‘factors’’ drug and the
interaction of drug with time were not statistically significant.
In the subgroup analysis, the effect time was significant
(p = 0.019), whereas ‘‘factors’’ drug and interaction of drug with
time failed to reach statistical significance. In the pairwise multiple
comparisons, the AUC after clonazepam was significantly lower
than after tolterodine at 120 min (p= 0.024). The AUC after
clonazepam significantly decreased from baseline at 120 min
(p = 0.003) and after administration of flumazenil (p = 0.007),
whereas no significant time effect for the other two drugs was
detected.
Psychomotor performance (DSST-Score)
The mean (SD) of the DSST-score for tolterodine, clobazam
und clonazepam 120 min after drug administration was 76.5
(11.7), 74.9 (14.7) and 69.3 (15.8), respectively. After flumazenil,
the values for tolterodine, clobazam und clonazepam were 81.5
(10.7), 81.1 (12.1) and 79.1 (14.5), respectively.
In the main analysis, the effect time (p,0.001) was statistically
significant whereas the effect drug and the interaction of drug with
time failed to show statistical significance. In the pairwise
comparison within the time-points, clonazepam (but not cloba-
zam) was significantly associated to a lower score than tolterodine
at 120 min (p = 0.031).
In the subgroup analysis, the interaction of drug and time
(p = 0.04) was statistically significant. The pairwise multiple
comparison showed a lower psychomotor performance with
clonazepam at 120 minutes, compared with the other two drugs
(p = 0.025). The score within clonazepam significantly increased
after flumazenil injection (p= 0.001).
No side effect other than impairment of psychomotor perfor-
mance was observed.
Pharmacokinetic and pharmacogenetic investigations
Table 5 presents the pharmacokinetic parameters of clobazam
in all subjects (n = 16) and in the subgroup that included the
volunteers with peak plasma levels of clobazam before adminis-
tration of flumazenil (Tmax beyond 180 minutes) and plasma
concentrations of at least 200 mg/ml during the same period
(n= 8). Five of remaining subjects had a Tmax longer than
180 minutes, which was the time of flumazenil administration.
Three more subjects had a maximal concentration (cmax) below
200 mg/ml at 120 minutes. We determined CYP 2C19 pheno-
type, and one of the 16 subjects was poor CYP2C19 metabolizer.
Discussion
This study analyzed the anti-hyperalgesic and analgesic effect of
two benzodiazepines in a multimodal experimental pain proce-
dure. The ultimate aim was to explore the potential of GABA-
agonism for future clinical research. Interactions between time and
drug, results of pairwise comparisons within the ANOVA, and
analyses that considered the pharmacokinetic variability are
suggestive for a possible anti-hyperalgesic or analgesic effect of
GABAergic drugs.
Primary endpoint
Capsaicin injection induces secondary hyperalgesia, a phenom-
enon related to central sensitization [26]. The method has been
used in several pharmacological studies. It could detect the effects
of different drugs, such as opioids, NMDA-antagonists and
anticonvulsants [27–29], whereas it did not reveal anti-hyperalge-
sic effects in some studies on cannabinoids and antidepressants
[30,31]. In another study on cannabinoids, the intensity of
capsaicin-induced pain, but not the area of hyperalgesia, detected
drug effects [32].
We found a statistically significant interaction of the ‘‘factors’’
drug and time. An increase in the area of static hyperalgesia was
observed after administration of placebo, but not after clobazam
and clonazepam. Our interpretation is that the benzodiazepines
prevented the increase in the area of hyperalgesia, thereby
Table 5. Pharmacokinetic parameters of clobazam.
Tmax (h)
Cmax
(ug/ml)
AUC
(h*ug/L) T1/2 (h)
All volunteers (n = 16) 2.28 (1.40) 0.37 (0.17) 5461 (2061) 19.02 (6.55)
Subgroup (n = 8) 1.64 (1.06) 0.47 (0.18) 6160 (1637) 17.50 (2.50)
The table reports the parameters in all volunteers and in the subgroup that
included the subjects with peak plasma levels of clobazam below 180 minutes
and plasma concentrations of at least 200 mg/ml during the same period (n = 8).
Data are expressed as mean values (SD).
doi:10.1371/journal.pone.0043896.t005
Figure 5. Intramuscular repeated electrical stimulation (5
stimuli). There was a statistically significant increase in the temporal
summation thresholds for clonazepam (p = 0.021) and clobazam
(p= 0.021) between baseline measures and 120 minutes, whereas no
statistically significant change in threshold after the active placebo
tolterodine was observed.
doi:10.1371/journal.pone.0043896.g005
Benzodiazepines in Human Experimental Pain
PLOS ONE | www.plosone.org 11 March 2013 | Volume 8 | Issue 3 | e43896
displaying an anti-hyperalgesic effect. This is consistent with the
large amount of animal data on GABA-agonists [4,5].
Secondary endpoints
Results suggestive for an analgesic effect of the benzodiazepines
were obtained with all three intramuscular pain models and with
cuff algometry. No analgesic effect could be detected with the
other pain models employed. The finding that muscle pain models
were particularly sensitive to the effects of the benzodiazepines is
consistent with a previous investigation on remifentanil: this opioid
caused a significantly higher increase in the electrical muscular
pain threshold than in the electrical cutaneous pain threshold [33].
The results of these two studies suggest that muscle pain models
may be important tools for future pharmacological investigations.
The results with intramuscular stimulation were more robust for
the model with repeated (five) stimulations, compared with single
stimulation. The 5 repeated stimuli induce temporal summation, a
phenomenon related with short-lasting central sensitization [21].
Interestingly, the NMDA-antagonist ketamine increased the pain
threshold to repeated stimulation, but had no effect on the pain
threshold after single stimulation [21]. This finding is consistent
with the established role of NMDA mechanisms in central
sensitization [34]. Accordingly, the effects of GABAergic drugs
may be better detected with models that induce temporal
summation, given the well-know role of GABA-receptors in
modulating spinal cord hyperexcitability [3].
Psychomotor performance
Clonazepam impaired psychomotor performance more than
clobazam and tolterodine. This effect was not observed anymore
after flumazenil. The results confirm previous data that clobazam
may be associated with less sedation than clonazepam, at least at
the doses investigated [8,9].
Effect of flumazenil
The effect of clobazam and clonazepam was not influenced by
flumazenil in most cases. Occasionally, the difference with placebo
persisted after administration of this drug. In our opinion, this is
likely the result of a too low dose of flumazenil. This dose was
chosen in order to minimize the risk of severe complications, such
as seizures, in our population of healthy subjects [14].
Pharmacokinetics and pharmacogenetics
Plasma levels of clobazam exhibited an unexpected high degree
of variability. Pharmacogenetic do not explain this variability,
since all except one subject were CYP 2C19 extensive metabo-
lizers. The reason for this variability is probably related to delayed
absorption. All subjects were tested in the morning and had been
instructed to take a very light breakfast at home. Considering the
transfer time to the research unit and the additional 2-hours time
before drug administration (interview, instruction, training of
tests), it is unlikely that our healthy subjects had still some gastric
content at the time of drug intake. Delayed absorption, whatever
the cause, still remains the most likely explanation for this finding.
Strengths and limitations
This study implied an extensive exploration of pain mecha-
nisms, including hyperalgesia, cutaneous and muscular pain
sensitivity, temporal summation, response to different types of
sensory stimuli and conditioned pain modulation. The same
investigator performed all the experiments. Pharmacokinetic and
pharmacogenetic investigations were included. We are not aware
of similar comprehensive studies in this area [7].
The study has also limitations. The capsaicin model does not
allow more than 2 h time for testing of hyperalgesia [17]. Based on
the pharmacokinetic results, an experimental model with a longer
time profile may be more sensitive in detecting the anti-
hyperalgesic effects of clobazam or possible active metabolites.
Our design implied a single dose administration, and the effect of
higher, repeated doses or long-term applications remain unclear.
Do benzodiazepines display anti-hyperalgesic and
analgesic action?
Research on benzodiazepines in clinical pain conditions is
sparse. A systematic review on intrathecal midazolam for
postoperative pain found some evidence of efficacy [35]. Another
systematic review on the efficacy of clonazepam in neuropathic
pain and fibromyalgia could not identify any studies that satisfied
the inclusion criteria [36].
We detected an effect of the drugs with part of the tests
employed. Thus, a conclusive answer to this question cannot be
given. However, in the context of experimental work in rodents
and humans, this partial result is not surprising. Failure to detect
efficacy with part of the experimental pain modalities is a common
finding also with drugs characterized by established clinical
efficacy [7,37]. Different experimental pain modalities likely
reflect different dimensions of nociceptive processes, as confirmed
by a recent large investigation on healthy subjects [38]. Drugs
probably affect these dimensions differentially, leading to different
sensitivities of pain models to the analgesic effect of drugs.
We cannot rule out that part of the results were positive by
chance. However, some arguments are suggestive for a true anti-
hyperalgesic and analgesic effect of the drugs investigated. For the
primary endpoint, a significant result was obtained with the main
analysis on the interaction of drug with time. The result on the
primary endpoint is consistent with the findings of basic research.
A further argument is the pattern of response that emerges by a
collective analysis of the secondary endpoints, as summarized in
table 4. None of the pressure pain modalities revealed an effect of
clobazam and clonazepam; none of the tests that employed von
Frey hair stimulation detected any effect; and none of the
cutaneous electrical pain tests yielded any significant result.
Conversely, all the three intramuscular pain tests were able to
detect analgesic effects of the benzodiazepines. These effects were
consistent with the findings obtained with cuff algometry, a model
that probably acts, at least in part, by nociceptive stimulation of
the muscles. Because of this cluster pattern, it is unlikely that the
significant effects that were detected are the result of chance.
Rather, they confirm the finding of the aforementioned study,
which found responses to different stimulation modalities to
represent distinct dimensions of pain perception [38]. Such
dimensions seem to be affected differently by analgesic drugs.
Accordingly, our study provides information for future investi-
gations that will analyze the effect of benzodiazepines. The data
indicate that models of deep pain and hyperalgesia are probably
most suited.
There was no difference between clobazam and clonazepam
regarding the effect on the primary endpoint, i.e. the area of static
hyperalgesia. However, clonazepam was associated with stronger
impairment of psychomotor performance. This suggests that
clobazam may offer potential advantages in the clinical manage-
ment of pain; further clinical investigations on this compound
would be desirable.
Conclusions and perspectives
The present study provides some evidence for an anti-
hyperalgesic and analgesic action of agonists at the benzodiaze-
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pine-binding site of GABAA receptors. The results are not
conclusive, since positive findings were obtained with part of the
analyses. Furthermore, the clinical significance of the possible
effects of the specific drugs investigated is questionable. Never-
theless, the data support further research in the field of GABA-
modulation. GABA-agonists that selectively act at subtypes of
GABAA-receptors produce potent antihyperalgesia in animal
models, in the absence of sedation [6,39,40]. Some subtypes of
GABAA receptor modulators were investigated in clinical studies
for the treatment of anxiety [41,42]. Analgesic or antihyperalgesic
actions of these selective compounds have not been tested in
humans. The perspective holds that, due to the minimally sedating
properties of these selective drugs, doses higher than for
unselective compounds might be used: the consequent higher
receptor occupancy could lead to significant anti-hyperalgesic or
analgesic effects in clinical pain conditions. Finally, the results of
the present study provide information on which models have to be
selected for future investigations: methods that induce hyperalgesia
and deep pain may be most promising for detecting the effects of
GABAA-agonists.
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